NCT06232291 is a clinical trial in Treatment-Resistant Depression, sponsored by Medical University of Gdansk.

Who is sponsoring NCT06232291?

NCT06232291 is sponsored by Medical University of Gdansk.

What condition does NCT06232291 study?

NCT06232291 studies Treatment-Resistant Depression, Major Depressive Disorder.

Is NCT06232291 still recruiting?

NCT06232291 is currently completed. Last updated 29 May 2024.

Last reviewed 2024-05-29 · How we verify

NCT06232291

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant Depression

Completed Last updated 29 May 2024

What this trial tests

trial in Treatment-Resistant Depression in 3 participants. Completed in 24 May 2024.

Timeline

21 April 2023

Primary endpoint
24 May 2024

24 May 2024

Quick facts

Lead sponsor	Medical University of Gdansk
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3
Start date	21 April 2023
Primary completion	24 May 2024
Estimated completion	24 May 2024
Sites	1 location across Poland

Conditions studied

Treatment-Resistant Depression — all drugs for Treatment-Resistant Depression →
Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

Medical University of Gdansk

Who can join

Eligibility, any sex, with Treatment-Resistant Depression or Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An observational-comparative study, without interfering with the treatment, based on an operationalized interview.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations.
Vekhova KA, Namiot ED, Jonsson J, Schiöth HB. · · 2025 · cited 17× · PMID 39428602 · DOI 10.1002/cpt.3478
Single arketamine in treatment resistant depression: Presentation of 3 cases with regard to sick-leave duration.
Włodarczyk A, Słupski J, Szarmach J, Cubała WJ. · · 2024 · cited 9× · PMID 38554563 · DOI 10.1016/j.ajp.2024.104016
Mechanism of antidepressant action of ketamine and differences between its two enantiomers.
Zhan J, Zhang Y, Tian H, Zhu X, et al · · 2025 · PMID 41929374 · DOI 10.1016/j.jatmed.2025.06.001

Verify or expand the search:

Other recruiting trials for Treatment-Resistant Depression

Currently open trials in the same condition.

NCT07108257 — Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for the Treatment of Refractory Bipolar Depression · NA · recruiting
NCT06341426 — Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin · Phase 2 · recruiting

Other Medical University of Gdansk trials

Trials by the same sponsor.

NCT07521280 — State-Based Rehabilitation for Youth Athletes With Osgood-Schlatter or Sever-Related Apophyseal Pain · NA · not yet recruiting
NCT07446517 — Low-Level Laser Therapy for Osgood-Schlatter or Sever Pain in Youth Athletes · NA · recruiting
NCT07449585 — Pericapsular Nerve Group Block Versus Intrathecal Morphine for Analgesia After Total Hip Arthroplasty · NA · not yet recruiting
NCT07397208 — Assessment of the Repeatability of Sublingual Microcirculation Function Measurements in Healthy Volunteers and Criticall · not yet recruiting
NCT07345403 — GENECARD - the Use of Genetic, Epigenetic, Metabolomic, Proteomic and Microbiotic Markers, Image and Voice Biomarker Ana · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06232291 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Gdansk
Last refreshed: 29 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06232291.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing